美金刚预防脑转移放疗后认知功能下降:随机安慰剂对照试验
这项前瞻性双盲安慰剂对照随机试验评估美金刚对脑转移患者放疗后认知功能的影响。6个月时安慰剂组认知下降显著高于美金刚组,美金刚还改善记忆、延迟回忆、言语流畅性和整体健康状况。
要点
- 美金刚改善记忆、延迟回忆、言语流畅性及整体健康状况,SRS亚组领域特异性认知保护更佳。
- 常见毒性为食欲下降(25.7% vs 12.5%)和胃刺激(7.5% vs 0%)。
核心结论
- 美金刚较安慰剂 preserves 认知功能并改善脑转移放疗患者的生活质量。
- 在SRS和HA/WBRT队列中均观察到获益。
研究设计与样本
- 前瞻性、双盲、安慰剂对照随机临床试验。
- 放疗方式包括SRS(n=75)和HA/WBRT(n=55)。
主要发现
- SRS亚组领域特异性认知保护更佳(P<0.001)。
- 整体健康状况美金刚组中位变化+33.3分,安慰剂组无变化,组间差异+33.3分(95%CI +16.7至+41.7;P<0.001)。
关键数值与推荐
- 美金刚20mg/d口服6个月。
- 最佳谷浓度118.06 ng/mL在5mg每日两次时达到;10mg每日两次时6.25%患者超过警戒阈值300 ng/mL。
- 常见毒性:食欲下降25.7% vs 12.5%,胃刺激7.5% vs 0%。
临床怎么用
- 脑转移患者接受SRS或HA/WBRT时可考虑使用美金刚20mg/d以保护认知功能。
- 需监测食欲下降和胃刺激等不良反应。
- 5mg每日两次可达最佳谷浓度,10mg每日两次时部分患者超警戒阈值。
局限性
- SRS亚组整体认知效应检验效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective, double-blind, placebo-controlled, randomized clinical trial evaluated the role of memantine in preventing cognitive decline following radiation therapy (RT) for brain metastases (BM). METHODS AND MATERIALS: Patients with BM undergoing either stereotactic radiosurgery (SRS) or whole-brain RT with or without hippocampal avoidance (HA/WBRT) were randomized to receive memantine (20 mg/d) or placebo for 6 months post-RT. Primary outcomes included cognitive function (Addenbrooke's Cognitive Examination), quality of life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Brain Cancer Module [EORTC QLQ-C30 and BN20]), white matter volume changes (magnetic resonance imaging T2-weighted fluid-attenuated inversion recovery), plasma memantine levels (liquid chromatography-tandem mass spectrometry), and adverse events (Common Terminology Criteria for Adverse Events v5.0). RESULTS: One hundred thirty patients were enrolled (memantine n = 66; placebo n = 64; SRS n = 75; HA/WBRT n = 55). At 6 months post-RT, cognitive decline was significantly higher in the placebo group (mean Addenbrooke's Cognitive Examination: 72.9 ± 20.2) than in the memantine group (83.9 ± 10.8; P = .005). Memantine improved memory (P < .001), delayed recall (P < .001), and verbal fluency (P = .007), with better domain-specific cognitive preservation in the SRS subgroup (P < .001). Memantine was associated with improved cognitive function in both HA/WBRT and SRS cohorts; the effect was statistically significant in HA/WBRT patients, whereas in the SRS subgroup, better domain-specific cognitive preservation was observed, but the global cognitive effect estimate was underpowered. Global health status improved with memantine (median change +33.3 points) but was unchanged with placebo (between-arm difference +33.3 points, 95% CI +16.7 to +41.7; P < 0.001). Common toxicities included appetite loss (25.7% vs 12.5%) and gastric irritation (7.5% vs 0%). White matter volume correlated negatively with cognitive decline (r = -0.544; P = .055). The optimal trough concentration (118.06 ng/mL) was achieved at 5 mg twice daily, whereas levels exceeded the alert threshold (300 ng/mL) at 10 mg twice daily for 6.25% of patients. CONCLUSIONS: Memantine preserved cognitive function relative to placebo and improved quality of life in patients receiving RT for BM, with benefits observed in both SRS and HA/WBRT cohorts.
引用
- Surendran HP, Dutta D, Sruthi K, et al. Memantine Prevents Radiation-Induced Cognitive Decline in Brain Metastases-A Randomized Placebo-Controlled Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42790603. doi:10.1016/j.ijrobp.2026.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。